202 related articles for article (PubMed ID: 27132755)
41. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.
Furiak NM; Ascher-Svanum H; Klein RW; Smolen LJ; Lawson AH; Montgomery W; Conley RR
Curr Med Res Opin; 2011 Apr; 27(4):713-30. PubMed ID: 21265593
[TBL] [Abstract][Full Text] [Related]
43. Did CATIE influence antipsychotic use?
Citrome L; Jaffe A; Martello D; Allingham B; Levine J
Psychiatr Serv; 2008 May; 59(5):476. PubMed ID: 18451000
[No Abstract] [Full Text] [Related]
44. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model.
Perlis RH; Ganz DA; Avorn J; Schneeweiss S; Glynn RJ; Smoller JW; Wang PS
J Clin Psychopharmacol; 2005 Oct; 25(5):427-34. PubMed ID: 16160617
[TBL] [Abstract][Full Text] [Related]
45. Risperidone versus haloperidol: II. Cost-effectiveness.
Davies A; Langley PC; Keks NA; Catts SV; Lambert T; Schweitzer I
Clin Ther; 1998; 20(1):196-213. PubMed ID: 9522115
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.
Tunis SL; Faries DE; Nyhuis AW; Kinon BJ; Ascher-Svanum H; Aquila R
Value Health; 2006; 9(2):77-89. PubMed ID: 16626411
[TBL] [Abstract][Full Text] [Related]
47. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
Yang YK; Tarn YH; Wang TY; Liu CY; Laio YC; Chou YH; Lee SM; Chen CC
Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
[TBL] [Abstract][Full Text] [Related]
48. The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia.
Chen L; McCombs JS; Park J
Value Health; 2008; 11(1):34-43. PubMed ID: 18237358
[TBL] [Abstract][Full Text] [Related]
49. Outcome in schizophrenia: beyond symptom reduction.
Meltzer HY
J Clin Psychiatry; 1999; 60 Suppl 3():3-7; discussion 8. PubMed ID: 10073370
[TBL] [Abstract][Full Text] [Related]
50. Schizophrenia interventions in Vietnam: primary results from a cost-effectiveness study.
Anh NQ; Linh BN; Ha NT; Phanthunane P; Huong NT
Glob Public Health; 2015; 10 Supppl 1():S21-39. PubMed ID: 25482499
[TBL] [Abstract][Full Text] [Related]
51. Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Québec.
Latimer E; Wynant W; Clark R; Malla A; Moodie E; Tamblyn R; Naidu A
Clin Schizophr Relat Psychoses; 2013 Apr; 7(1):33-41. PubMed ID: 23367500
[TBL] [Abstract][Full Text] [Related]
52. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.
Glazer WM; Johnstone BM
J Clin Psychiatry; 1997; 58 Suppl 10():50-4. PubMed ID: 9265917
[TBL] [Abstract][Full Text] [Related]
53. [Medico-economic evaluation of treatment with clozapine versus treatment with previous neuroleptics].
Geronimi-Ferret D; Lesay M; Barges-Bertocchio MH; Cornet-Bonnefont M; Robert H
Encephale; 1997 Sep; 23 Spec No 4():24-31. PubMed ID: 9417402
[TBL] [Abstract][Full Text] [Related]
54. Clozapine for refractory schizophrenia: the Illinois experience.
Buckman RW; Malan RD
J Clin Psychiatry; 1999; 60 Suppl 1():18-22; discussion 28-30. PubMed ID: 10037166
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness analysis of olanzapine and risperidone in Norway.
Kim K; Aas E
J Ment Health Policy Econ; 2011 Sep; 14(3):125-35. PubMed ID: 22116170
[TBL] [Abstract][Full Text] [Related]
56. The pharmacoeconomics of clozapine: a review.
Meltzer HY; Cola PA
J Clin Psychiatry; 1994 Sep; 55 Suppl B():161-5. PubMed ID: 7961564
[TBL] [Abstract][Full Text] [Related]
57. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.
Ascher-Svanum H; Nyhuis AW; Faries DE; Kinon BJ; Baker RW; Shekhar A
Schizophr Bull; 2008 Nov; 34(6):1163-71. PubMed ID: 18156640
[TBL] [Abstract][Full Text] [Related]
58. The impact of schizophrenic patient functionality on service utilization and cost. Based on a presentation by Sandra L. Tunis, PhD.
Am J Manag Care; 1999 Jul; 5(10 Suppl):S583-90. PubMed ID: 10539493
[TBL] [Abstract][Full Text] [Related]
59. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment.
Neumann PJ
J Clin Psychiatry; 1999; 60 Suppl 3():9-14; discussion 15. PubMed ID: 10073371
[TBL] [Abstract][Full Text] [Related]
60. Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia.
Faries DE; Ascher-Svanum H; Nyhuis AW; Kinon BJ
BMC Psychiatry; 2009 Sep; 9():54. PubMed ID: 19725969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
